Appendix 1. Questionnaire

6.

Myocardial infarction

If you consent to participate in this survey, please put a check mark in the □ below and write the date on which you responded to the survey. □ I hereby consent to participate in this study. Response date (using the format Month/Day/Year): ____/2021 1) The following questions are about you. For multiple-choice questions, please circle the answer that applies to you. For questions that include parentheses (), please write your answer inside the parentheses. Age () years Sex 1. Male 2. Female Height () cm Weight () kg History of smoking 3. Yes 4. No History of alcohol consumption 1. Yes 2. No Medical history (past illnesses) 1. Hypertension 2. Diabetes 3. Dyslipidemia 4. Bronchial asthma Chronic obstructive pulmonary disease (COPD) 5.

9. Immune deficiency disease					
10. Chronic kidney disease					
11. Other ()					
Obstetric history (women)					
1. I had a pregnancy before I was infected v	with core	onavirus.			
2. I was pregnant when I was infected with	ı coronav	virus.			
3. I have never been pregnant.					
2) The following questions are about the course of the answers that apply to you.	i your co	ronavirus	infection	n. Please	
I was diagnosed with pneumonia	1.	Yes	2.	No	3. I don't know
I was administered oxygen once or more	1.	Yes	2.	No	3. I don't know
I was put on a ventilator once or more	1.	Yes	2.	No	3. I don't know
I was treated with ECMO once or more	1.	Yes	2.	No	3. I don't know
I was prescribed antivirals ¹	1.	Yes	2.	No	3. I don't know
I was prescribed steroids ²	1.	Yes	2.	No	3. I don't know
Notes: 1) Antivirals are drugs used to COVID-1	9, such	as remdesi	ivir (Vel	klury), fav	ripiravir
(Avigan), ivermectin (Stromectol), lopinavir/rito	onavir (H	Kaletra), h	ydroxyc	hloroquin	e
(Plaquenil), and azithromycin (Zithromax).					
2) Steroids refer to drugs that inhibit inflammati	ion, such	as dexam	ethason	e (Dexart)),
prednisolone (Predonin), and methylprednisolon	ne (Solu-	Medrol).			
3) The following questions are about the aftereffect	ts of CO	VID-19. I	Please n	ote wheth	er you

experienced the following symptoms. If yes, please write the duration of that symptom in days.

If you are unsure, please write the approximate duration.

7.

Melanoma

Connective tissue/rheumatic disease

respond as follows:		
(b. Yes)	2. No	
1. If yes, A. Since infection	©B. Since day (30)	after infection
(a). For (20) days	b. Ongoing	
Fever		
1. Yes	2. No	
1. If yes, A. Since infection infection	B. Since day () after
a. For () days	b. Ongoing	
Fatigue (Sluggishness)		
1. Yes	2. No	
1. If yes, A. Since infection infection	B. Since day () after
a. For () days	b. Ongoing	
Shortness of breath (Difficulty breathing)		
1. Yes	2. No	
1. If yes, A. Since infection infection	B. Since day () after
a. For () days	b. Ongoing	
Joint pain		
1. Yes	2. No	

Example: If you had a symptom for 20 days starting on day 30 after coronavirus infection, please

1. If yes, A. Since infection	B. Since day	() after
infection			
a. For () days	b. Ongoing		
Myalgia (Muscle pain)			
1. Yes	2. No		
1. If yes, A. Since infection infection	B. Since day	() after
a. For () days	b. Ongoing		
Chest pain			
1. Yes	2. No		
1. If yes, A. Since infection	B. Since day	() after
infection			
a. For () days	b. Ongoing		
Cough			
1. Yes	2. No		
1. If yes, A. Since infection	B. Since day	() after
infection			
a. For () days	b. Ongoing		
Abdominal pain (Stomach pain)			
1. Yes	2. No		
1. If yes, A. Since infection	B. Since day	() after
infection			

a. For () days	b. Ongoing
Dysosmia (loss of smell)	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Dysgeusia (loss of taste)	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Nasal discharge	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Bloodshot eyes	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing

Headache	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Phlegm	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Sore throat	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Diarrhea	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing
Nausea/vomiting	
1. Yes	2. No

1. If yes, A. Since infection	B. Since day	() after
infection		
a. For () days	b. Ongoing	
Loss of appetite		
1. Yes	2. No	
1. If yes, A. Since infection	B. Since day	() after
infection		
a. For () days	b. Ongoing	
Hair loss		
1. Yes	2. No	
1. If yes, A. Since infection	B. Since day	() after
infection		
a. For () days	b. Ongoing	
i. In patches	ii. Diffuse hair loss	iii. Don't know
Depression		
1. Yes	2. No	
1. If yes, A. Since infection	B. Since day	() after
infection		
a. For () days	b. Ongoing	
Loss of concentration		
1. Yes	2. No	
1. If yes, A. Since infection	B. Since day	() after

a. For () days	b. Ongoing
Memory disturbance (forgetfulness)	
1. Yes	2. No
1. If yes, A. Since infection	B. Since day () after
infection	
a. For () days	b. Ongoing

infection

Appendix 2. The number of the participants with COVID-19 symptoms and their persistence

symptoms	Number (%a)	Lasting more than 4	Lasting more than	Late onset (%b)
		weeks (%a)	12 weeks (% ^a)	
fever	293 (64.1)	12 (2.6)	1 (0.2)	2 (0.7)
fatigue	292 (64.0)	93 (20.4)	47 (10.3)	8 (2.7)
dysosmia	219 (47.9)	104 (22.8)	62 (13.6)	4 (1.8)
cough	214 (46.8)	68 (14.9)	21 (4.6)	4 (1.9)
dysgeusia	185 (40.6)	69 (15.1)	30 (6.6)	2 (1.1)
headache	173 (37.9)	32 (7.0)	18 (3.9)	3 (1.7)
LoA	171 (37.6)	24 (5.3)	9 (2.0)	0 (0)
SoB	163 (35.7)	55 (12.0)	25 (5.5)	4 (2.5)
joint pain	153 (33.5)	20 (4.4)	15 (3.3)	5 (3.3)
sore throat	139 (30.5)	12 (2.6)	5 (1.1)	1 (0.7)
LoC	137 (30.0)	95 (20.8)	70 (15.3)	10 (7.3)
depression	125 (27.5)	79 (17.3)	55 (12.0)	16 (12.8)
myalgia	113 (24.7)	16 (3.5)	11 (2.4)	3 (2.7)
diarrhea	111 (24.3)	6 (1.3)	4 (0.9)	2 (1.8)


sputum	109 (23.9)	25 (5.5)	13 (2.8)	2 (1.8)
hair loss	103 (22.7)	73 (16.0)	29 (6.3)	58 (56.3)
MD	102 (22.5)	88 (19.3)	78 (17.1)	17 (16.7)
runny nose	96 (21.1)	14 (3.1)	9 (2.0)	0 (0)
chest pain	92 (20.1)	32 (7.0)	18 (3.9)	7 (7.6)
abdominal	47 (10.3)	3 (0.7)	1 (0.2)	0 (0)
pain				
nausea	36 (7.9)	4 (0.9)	3 (0.7)	0 (0)
conjunctivitis	32 (7.0)	4 (0.9)	1 (0.2)	0 (0)

Abbreviations: LoA, loss of appetite; SoB, shortness of breath; LoC, loss of concentration; MD, memory disturbance.


^aCalculated by dividing the number of patients by the total number of participants (n =457).

^bCalculated by dividing the number of patients by the number of participants who experienced the symptoms (N=457).


Appendix 3. Acute symptoms associated with COVID-19




Appendix 4a. Risk factors for development of fatigue in patients with COVID-19




Appendix 4b. Risk factors for persistence of fatigue among patients with fatigue




Appendix 5a. Risk factors for development of dysgeusia in patients with COVID-19




Appendix 5b. Risk factors for persistence of dysgeusia among patients with dysgeusia



Appendix 6a. Risk factors for development of dysosmia in patients with COVID-19



Appendix 6b. Risk factors for persistence of dysosmia among patients with dysosmia



Appendix 7. Risk factors for development of hair loss in patients with COVID-19

